The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Addex Therapeutics Pretax Margin % Related Terms
Addex Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Addex Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APE1 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Addex Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Addex Therapeutics (FRA:APE1) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Addex Therapeutics and its competitors. According to the industry distribution chart, Addex Therapeutics ranks #901 out of 942 companies in the Biotechnology industry, placing it in the top 95.6%.
Is Addex Therapeutics' Pretax Margin % too high?
Addex Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Addex Therapeutics ranks #901 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #901 out of 942 companies for Pretax Margin %. This places Addex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Pretax Margin % of %. The stock's GF Value™ is €1.24, compared to a current price of €5.10 — trading 311.3% above its estimated fair value. The current Pretax Margin % is %. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?
Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued.
The current stock price of €5.10 is trading 311.3% above its estimated GF Value™ of €1.24.
Key valuation signals for FRA:APE1:
Pretax Margin %: %
GF Value™: €1.24 vs. price of €5.10 (311.3% above fair value)
No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score
Get the complete analysis for FRA:APE1
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE1 has been successfully added to your 
